Insmed continues to expect full-year 2022 global revenues for ARIKAYCE to increase 30% year over year from 2021. For the full year 2023, Insmed anticipates ARIKAYCE global revenues will be between $285M-$300M. Insmed is advancing the development of ARIKAYCE in a frontline setting of patients newly diagnosed with MAC lung disease, consisting of the postmarketing confirmatory ARISE and ENCORE trials. Enrollment is complete in ARISE and Insmed anticipates sharing topline efficacy and safety data from the study in the third quarter of 2023. The company reported a treatment discontinuation rate in ARISE of 15%, which is less than half the discontinuation rate observed in the pivotal CONVERT trial of ARIKAYCE in patients with refractory MAC lung disease. The company continues to anticipate completing enrollment in ENCORE by the end of 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INSM:
